BrainsWay Ltd. (BWAY) Stock

Healthcare · Medical Devices · Member of Other US Stocks

BrainsWay Ltd. (BWAY) closed at USD 11.51 on 2026-10-14, a change of +38.8 % over the past year, with a market capitalization of USD 475.79M.

BrainsWay Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

BrainsWay Ltd. key figures

Previous close

USD 11.51 (2026-10-14)

1-year change

+38.8 %

Market cap

USD 475.79M

Enterprise value

USD 419.35M

P/E ratio (trailing)

51.39

P/E ratio (forward)

23.33

EPS (trailing)

0.23

EPS (forward)

0.51

PEG ratio

n/a

Price to book

5.99

Revenue growth

35.4 %

Earnings growth

59.8 %

Dividend per share (trailing)

0.00

Short ratio

2.78

Employees

129

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About BrainsWay Ltd.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for BrainsWay Ltd. and compare it with other stocks.